Physician profile
Raphaella Tran
NPI 1528636198
$3,833.70
in general payments reported to CMS, 2019-2025
18 companies · $908 in 2025
The $908 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $783 · 2023: $979 · 2024: $1,164 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781 · Consulting Fee: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.01 |
| Consulting Fee | $270.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $830.64 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $808.80 | 2022-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $756.84 | 2022-2025 | Dailies Total1, Tryptyr, Rocklatan |
| Visioneering Technologies, INC. | $169.11 | 2022-2023 | |
| Harrow Eye, LLC | $160.60 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $155.84 | 2022-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $154.14 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $152.23 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $124.94 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $122.06 | 2022-2024 | Cequa |
| Thea Pharma INC. | $91.48 | 2023 | |
| Abbvie INC. | $71.14 | 2022-2024 | Vuity |
| Astellas Pharma US INC | $68.40 | 2024-2025 | Izervay |
| Amgen INC. | $58.28 | 2024 | Tepezza |
| Dompe US, INC. | $45.30 | 2024-2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $27.17 | 2025 | |
| Biotissue Holdings INC. | $20.31 | 2025 | |
| Spark Therapeutics, INC. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphaella Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.